WO2013052424A3 - Compositions for enhancing nail health - Google Patents

Compositions for enhancing nail health Download PDF

Info

Publication number
WO2013052424A3
WO2013052424A3 PCT/US2012/058333 US2012058333W WO2013052424A3 WO 2013052424 A3 WO2013052424 A3 WO 2013052424A3 US 2012058333 W US2012058333 W US 2012058333W WO 2013052424 A3 WO2013052424 A3 WO 2013052424A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
health
nail
enhancing
nail health
Prior art date
Application number
PCT/US2012/058333
Other languages
French (fr)
Other versions
WO2013052424A2 (en
Inventor
John G. Walt
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to CN201280059691.1A priority Critical patent/CN103987370A/en
Priority to JP2014534627A priority patent/JP2014528447A/en
Priority to CA2851346A priority patent/CA2851346A1/en
Priority to AU2012318823A priority patent/AU2012318823A1/en
Priority to KR1020147011967A priority patent/KR20140096048A/en
Priority to EP12775399.4A priority patent/EP2763649A2/en
Priority to BR112014008172A priority patent/BR112014008172A2/en
Publication of WO2013052424A2 publication Critical patent/WO2013052424A2/en
Publication of WO2013052424A3 publication Critical patent/WO2013052424A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention is directed to compositions and methods for enhancing the health of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to enhance nail health. The composition is also effective in strengthening and growing nails. The composition comprises an immunomodulator which is preferably cyclosporine.
PCT/US2012/058333 2011-10-05 2012-10-01 Compositions for enhancing nail health WO2013052424A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN201280059691.1A CN103987370A (en) 2011-10-05 2012-10-01 Compositions for enhancing nail health
JP2014534627A JP2014528447A (en) 2011-10-05 2012-10-01 Composition for improving nail health
CA2851346A CA2851346A1 (en) 2011-10-05 2012-10-01 Compositions for enhancing nail health
AU2012318823A AU2012318823A1 (en) 2011-10-05 2012-10-01 Compositions for enhancing nail health
KR1020147011967A KR20140096048A (en) 2011-10-05 2012-10-01 Compositions for enhancing nail health
EP12775399.4A EP2763649A2 (en) 2011-10-05 2012-10-01 Compositions for enhancing nail health
BR112014008172A BR112014008172A2 (en) 2011-10-05 2012-10-01 nail health enhancing compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161543758P 2011-10-05 2011-10-05
US61/543,758 2011-10-05

Publications (2)

Publication Number Publication Date
WO2013052424A2 WO2013052424A2 (en) 2013-04-11
WO2013052424A3 true WO2013052424A3 (en) 2013-11-14

Family

ID=47046873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/058333 WO2013052424A2 (en) 2011-10-05 2012-10-01 Compositions for enhancing nail health

Country Status (10)

Country Link
EP (1) EP2763649A2 (en)
JP (1) JP2014528447A (en)
KR (1) KR20140096048A (en)
CN (1) CN103987370A (en)
AR (1) AR088234A1 (en)
AU (1) AU2012318823A1 (en)
BR (1) BR112014008172A2 (en)
CA (1) CA2851346A1 (en)
TW (1) TW201321025A (en)
WO (1) WO2013052424A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
WO2007008894A2 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
EP1958638A1 (en) * 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans to increase nail growth rate
WO2010080913A1 (en) * 2009-01-08 2010-07-15 Allergan, Inc. Cyclosporine compositions for enhancing nail growth

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (en) 1978-03-07 1979-09-13 Sandoz Ag NEW RESORBABLE GALENIC COMPOSITIONS
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP1163254B1 (en) 1999-02-26 2008-01-30 The University of British Columbia Trpm-2 antisense therapy
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
WO2007008894A2 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
EP1958638A1 (en) * 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans to increase nail growth rate
WO2010080913A1 (en) * 2009-01-08 2010-07-15 Allergan, Inc. Cyclosporine compositions for enhancing nail growth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANNAVÒ S P ET AL: "Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study", DERMATOLOGY, S. KARGER AG, CH, vol. 206, no. 2, 1 January 2003 (2003-01-01), pages 153 - 156, XP009134400, ISSN: 1018-8665 *
JIARAVUTHISAN ET AL: "Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 57, no. 1, 1 July 2007 (2007-07-01), pages 1 - 27, XP022111711, ISSN: 0190-9622, DOI: 10.1016/J.JAAD.2005.07.073 *
SYUTO TOMOKO ET AL: "Successful treatment of psoriatic nails with low-dose cyclosporine administration", EUROPEAN JOURNAL OF DERMATOLOGY, JOHN LIBBEY EUROTEXT, FR, vol. 17, no. 3, 1 May 2007 (2007-05-01), pages 248 - 249, XP002585865, ISSN: 1167-1122 *

Also Published As

Publication number Publication date
JP2014528447A (en) 2014-10-27
AR088234A1 (en) 2014-05-21
EP2763649A2 (en) 2014-08-13
AU2012318823A1 (en) 2014-04-24
KR20140096048A (en) 2014-08-04
CA2851346A1 (en) 2013-04-11
WO2013052424A2 (en) 2013-04-11
BR112014008172A2 (en) 2017-04-18
TW201321025A (en) 2013-06-01
CN103987370A (en) 2014-08-13

Similar Documents

Publication Publication Date Title
MY155235A (en) Cyclosporine compositions for enhancing nail growth
MX338535B (en) Ibat inhibitors for the treatment of liver diseases.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2871471C (en) Dna-pk inhibitors
MX358978B (en) Exopolysaccharide for the treatment and/or care of the skin, mucous membranes, hair and/or nails.
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
PH12015500301B1 (en) A novel formulation of diclofenac
EA201291357A1 (en) TREATMENT METHODS USING TLR7 AND / OR TLR9 INHIBITORS
WO2009135006A3 (en) Methods for preventing oxidative damage to hair and promote hair shine
MX360019B (en) A novel formulation of metaxalone.
MY159208A (en) A novel formulation of indomethacin
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
WO2013052380A3 (en) Compositions for enhancing nail health
ZA201108335B (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
WO2012130820A3 (en) Isopentyl esters for the use in cosmetic, dermatological, or pharmaceutical compositions
MX2019012375A (en) Lfa-1 inhibitor formulations.
WO2013052424A3 (en) Compositions for enhancing nail health
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
BR112014004737A2 (en) Ambroxol Hydrochloride Compound Compound and Method of Preparation of Compound
WO2011061700A3 (en) Ifnϒ inhibitors in the treatment of motoneuron diseases
WO2012169860A3 (en) Composition for preventing hair loss or promoting hair restoration, comprising soy extract
AR082594A1 (en) PANTENYL DOCOSAHEXANOATE AND ITS USE FOR THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
IT1394921B1 (en) USE OF COMPOUNDS AS ACTIVE PRINCIPLES TO IMPROVE THE CELL REPAIR ACTION OF THE HUMAN EPIDERMISAL, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT CONTAIN THEM
WO2012096463A3 (en) Composition containing a mixed herbal extract as an active ingredient for preventing and improving allergic or non-allergic skin disease, and uses thereof
UA105653C2 (en) Use of cyclosporine composition for enhancing nail growth

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2014534627

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2851346

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2012775399

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012775399

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012318823

Country of ref document: AU

Date of ref document: 20121001

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147011967

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014117113

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014008172

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12775399

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112014008172

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140404